A Phase II Study Evaluating The Efficacy And Tolerability Of Everolimus (RAD001) In Combination With Trastuzumab And Vinorelbine In The Treatment Of Progressive HER2-Positive Breast Cancer Brain Metastases.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Everolimus (Primary) ; Trastuzumab; Vinorelbine
- Indications Advanced breast cancer; Brain metastases
- Focus Therapeutic Use
- 26 Jun 2017 Planned End Date changed from 19 May 2017 to 4 May 2019.
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 10 Mar 2017 Planned End Date changed from 1 Dec 2017 to 19 May 2017.